Tirzepatide FDA Approved Tirzepatide (LY3298176) Category Weight Loss & Metabolism AliasesMounjaro, Zepbound, LY3298176 AdministrationSubcutaneous injection (once weekly) OverviewHow it worksTimingBenefitsSide effectsResearchSources Research and regulatory 📋 Development stage FDA approved: T2D (2022), obesity (2023). ⚖️ Legal and regulatory FDA approved — Mounjaro (T2D), Zepbound (obesity). ⚠️ Side effects Nausea, vomiting, diarrhea; rare pancreatitis risk